Cargando…
Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies
Coronavirus disease 2019 (COVID-19) continues to significantly impact the global population, thus countermeasure platforms that enable rapid development of therapeutics against variants of SARS-CoV-2 are essential. We report use of a phage display human antibody library approach to rapidly identify...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476467/ https://www.ncbi.nlm.nih.gov/pubmed/36109550 http://dx.doi.org/10.1038/s41598-022-19780-7 |
| _version_ | 1784790144243466240 |
|---|---|
| author | Cao, Xia Maruyama, Junki Zhou, Heyue Fu, Yanwen Kerwin, Lisa Powers, Colin Sattler, Rachel A. Manning, John T. Singh, Alok Lim, Reyna Healy, Laura D. Johnson, Sachi Paz Cabral, Elizabeth Li, Donghui Lu, Lucy Ledesma, Arthur Lee, Daniel Richards, Susan Rivero-Nava, Laura Li, Yan Shen, Weiqun Stegman, Karen Blair, Benjamin Urata, Shinji Kishimoto-Urata, Magumi Ko, Jamie Du, Na Morais, Kyndal Lawrence, Kate Rivera, Ianne Pai, Chin-I. Bresson, Damien Brunswick, Mark Zhang, Yanliang Ji, Henry Paessler, Slobodan Allen, Robert D. |
| author_facet | Cao, Xia Maruyama, Junki Zhou, Heyue Fu, Yanwen Kerwin, Lisa Powers, Colin Sattler, Rachel A. Manning, John T. Singh, Alok Lim, Reyna Healy, Laura D. Johnson, Sachi Paz Cabral, Elizabeth Li, Donghui Lu, Lucy Ledesma, Arthur Lee, Daniel Richards, Susan Rivero-Nava, Laura Li, Yan Shen, Weiqun Stegman, Karen Blair, Benjamin Urata, Shinji Kishimoto-Urata, Magumi Ko, Jamie Du, Na Morais, Kyndal Lawrence, Kate Rivera, Ianne Pai, Chin-I. Bresson, Damien Brunswick, Mark Zhang, Yanliang Ji, Henry Paessler, Slobodan Allen, Robert D. |
| author_sort | Cao, Xia |
| collection | PubMed |
| description | Coronavirus disease 2019 (COVID-19) continues to significantly impact the global population, thus countermeasure platforms that enable rapid development of therapeutics against variants of SARS-CoV-2 are essential. We report use of a phage display human antibody library approach to rapidly identify neutralizing antibodies (nAbs) against SARS-CoV-2. We demonstrate the binding and neutralization capability of two nAbs, STI-2020 and STI-5041, against the SARS-CoV-2 WA-1 strain as well as the Alpha and Beta variants. STI-2020 and STI-5041 were protective when administered intravenously or intranasally in the golden (Syrian) hamster model of COVID-19 challenged with the WA-1 strain or Beta variant. The ability to administer nAbs intravenously and intranasally may have important therapeutic implications and Phase 1 healthy subjects clinical trials are ongoing. |
| format | Online Article Text |
| id | pubmed-9476467 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94764672022-09-15 Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies Cao, Xia Maruyama, Junki Zhou, Heyue Fu, Yanwen Kerwin, Lisa Powers, Colin Sattler, Rachel A. Manning, John T. Singh, Alok Lim, Reyna Healy, Laura D. Johnson, Sachi Paz Cabral, Elizabeth Li, Donghui Lu, Lucy Ledesma, Arthur Lee, Daniel Richards, Susan Rivero-Nava, Laura Li, Yan Shen, Weiqun Stegman, Karen Blair, Benjamin Urata, Shinji Kishimoto-Urata, Magumi Ko, Jamie Du, Na Morais, Kyndal Lawrence, Kate Rivera, Ianne Pai, Chin-I. Bresson, Damien Brunswick, Mark Zhang, Yanliang Ji, Henry Paessler, Slobodan Allen, Robert D. Sci Rep Article Coronavirus disease 2019 (COVID-19) continues to significantly impact the global population, thus countermeasure platforms that enable rapid development of therapeutics against variants of SARS-CoV-2 are essential. We report use of a phage display human antibody library approach to rapidly identify neutralizing antibodies (nAbs) against SARS-CoV-2. We demonstrate the binding and neutralization capability of two nAbs, STI-2020 and STI-5041, against the SARS-CoV-2 WA-1 strain as well as the Alpha and Beta variants. STI-2020 and STI-5041 were protective when administered intravenously or intranasally in the golden (Syrian) hamster model of COVID-19 challenged with the WA-1 strain or Beta variant. The ability to administer nAbs intravenously and intranasally may have important therapeutic implications and Phase 1 healthy subjects clinical trials are ongoing. Nature Publishing Group UK 2022-09-15 /pmc/articles/PMC9476467/ /pubmed/36109550 http://dx.doi.org/10.1038/s41598-022-19780-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Article Cao, Xia Maruyama, Junki Zhou, Heyue Fu, Yanwen Kerwin, Lisa Powers, Colin Sattler, Rachel A. Manning, John T. Singh, Alok Lim, Reyna Healy, Laura D. Johnson, Sachi Paz Cabral, Elizabeth Li, Donghui Lu, Lucy Ledesma, Arthur Lee, Daniel Richards, Susan Rivero-Nava, Laura Li, Yan Shen, Weiqun Stegman, Karen Blair, Benjamin Urata, Shinji Kishimoto-Urata, Magumi Ko, Jamie Du, Na Morais, Kyndal Lawrence, Kate Rivera, Ianne Pai, Chin-I. Bresson, Damien Brunswick, Mark Zhang, Yanliang Ji, Henry Paessler, Slobodan Allen, Robert D. Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies |
| title | Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies |
| title_full | Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies |
| title_fullStr | Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies |
| title_full_unstemmed | Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies |
| title_short | Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies |
| title_sort | unbiased approach to identify and assess efficacy of human sars-cov-2 neutralizing antibodies |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476467/ https://www.ncbi.nlm.nih.gov/pubmed/36109550 http://dx.doi.org/10.1038/s41598-022-19780-7 |
| work_keys_str_mv | AT caoxia unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT maruyamajunki unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT zhouheyue unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT fuyanwen unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT kerwinlisa unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT powerscolin unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT sattlerrachela unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT manningjohnt unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT singhalok unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT limreyna unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT healylaurad unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT johnsonsachi unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT pazcabralelizabeth unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT lidonghui unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT lulucy unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT ledesmaarthur unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT leedaniel unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT richardssusan unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT riveronavalaura unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT liyan unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT shenweiqun unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT stegmankaren unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT blairbenjamin unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT uratashinji unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT kishimotouratamagumi unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT kojamie unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT duna unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT moraiskyndal unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT lawrencekate unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT riveraianne unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT paichini unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT bressondamien unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT brunswickmark unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT zhangyanliang unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT jihenry unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT paesslerslobodan unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT allenrobertd unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies |